de Virgilio C, Cherry K J, Gloviczki P, Naessens J, Bower T, Hallett J, Pairolero P
Department of Surgery, Mayo Clinic, Rochester, Minn. 55905, USA.
Ann Vasc Surg. 1995 Sep;9(5):459-66. doi: 10.1007/BF02143860.
To determine optimal management and outcome of infected extra-anatomic bypass grafts (EABG), we reviewed 28 patients (19 men and 9 women; mean age 70 years) treated over a 13-year period. Mean follow-up was 42 months. There were 16 axillofemoral (AF), 10 femorofemoral (FF), and two axillopopliteal (AP) grafts. Risk factors included previous prosthetic graft infection in 13 patients, enterocutaneous fistula in two, and mycotic aortic aneurysm in one. Initial management involved complete graft excision in 12 patients, partial graft excision in 10, and nonresectional therapy in six. Failure of nonresectional therapy and partial excision in three patients each required further operative intervention with graft excision. Reconstruction in patients eventually requiring graft excision (n = 25) entailed placement of a new prosthetic AF or AP graft in eight, an autogenous FF graft in five, combined prosthetic AF and autogenous FF bypass in two, autogenous iliofemoral bypass in one, obturator bypass in one, or no reconstruction in eight. Four autogenous FF reconstructions thrombosed immediately postoperatively, and three prosthetic reconstructions became infected. The mortality rate was 18% (FF = 20%, AF = 19%, AP = 0%). The amputation rate was 25% (AP = 100%, AF = 25%, FF = 10%) and was higher without arterial reconstruction (56% vs. 12%, p = 0.02). Two patients required hemipelvectomies and one had bilateral hip disarticulation. We conclude that EABG infections can be successfully treated but carry significant morbidity and mortality. Optimal management includes EABG resection and prompt revascularization, bearing in mind the risk of early thrombosis in autogenous grafts and reinfection in prosthetic grafts.
为了确定感染性解剖外旁路移植术(EABG)的最佳治疗方法和预后,我们回顾了13年间接受治疗的28例患者(19例男性和9例女性;平均年龄70岁)。平均随访时间为42个月。其中有16例腋股(AF)旁路移植、10例股股(FF)旁路移植和2例腋腘(AP)旁路移植。危险因素包括13例患者既往有人工血管移植感染、2例患者有肠皮肤瘘、1例患者有霉菌性主动脉瘤。初始治疗包括12例患者进行完全血管移植切除、10例患者进行部分血管移植切除、6例患者进行非切除治疗。3例患者非切除治疗和部分切除失败,均需要进一步手术干预进行血管移植切除。最终需要进行血管移植切除的患者(n = 25)中,8例患者植入了新的人工AF或AP血管移植、5例患者植入了自体FF血管移植、2例患者采用人工AF和自体FF联合旁路移植、1例患者采用自体髂股旁路移植、1例患者采用闭孔旁路移植,8例患者未进行重建。4例自体FF重建术后立即发生血栓形成,3例人工血管重建发生感染。死亡率为18%(FF = 20%,AF = 19%,AP = 0%)。截肢率为25%(AP = 100%,AF = 25%,FF = 10%),未进行动脉重建的患者截肢率更高(56%对12%,p = 0.02)。2例患者需要进行半骨盆切除术,1例患者进行了双侧髋关节离断术。我们得出结论,EABG感染可以成功治疗,但具有显著的发病率和死亡率。最佳治疗方法包括EABG切除和及时的血管重建,同时要考虑到自体血管移植早期血栓形成和人工血管移植再感染的风险。